w3a4ogc2

Property	Value
?:abstract	Drug-drug interactions (DDI) potentially occurring between medications used in the course of COVID-19 infection and medications prescribed for the management of underlying comorbidities may cause adverse drug reactions (ADRs) contributing to worsening of the clinical outcome in affected patients. First, we conducted a meta-analysis to determine comorbidities observed in the course of COVID-19 disease associated with an increased risk of worsened clinical outcome from 24 published studies. In addition, the potential risk of DDI between medications used in the course of COVID-19 treatment in these studies and those for the management of observed comorbidities was evaluated for possible worsening of the clinical outcome. Our meta-analysis revealed an implication cardiometabolic syndrome (e.g. cardiovascular disease, cerebrovascular disease, hypertension, and diabetes), chronic kidney disease and chronic obstructive pulmonary disease as main co-morbidities associated with worsen the clinical outcomes including mortality (risk difference RD 0.12, 95%-CI 0.05-0.19, p = 0.001), admission to ICU (RD 0.10, 95%-CI 0.04-0.16, p = 0.001) and severe infection (RD 0.05, 95%-CI 0.01-0.09, p = 0.01) in COVID-19 patients. Potential DDI on pharmacokinetic level were identified between the antiviral agents atazanavir and lopinavir/ritonavir and some drugs, used in the treatment of cardiovascular diseases such as antiarrhythmics and anti-coagulants possibly affecting the clinical outcome including cardiac injury or arrest because of QTc-time prolongation or bleeding. Concluding, DDI occurring in the course of anti-Covid-19 treatment and co-morbidities could lead to ADRs, increasing the risk of hospitalization, prolonged time to recovery or death on extreme cases. COVID-19 patients with cardiometabolic diseases, chronic kidney disease and chronic obstructive pulmonary disease should be subjected to particular carefully clinical monitoring of adverse events with a possibility of dose adjustment when necessary.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/w3a4ogc2_hasAnnotation_C0003195> <https://research.tib.eu/covid-19/entity/w3a4ogc2_hasAnnotation_C0003451> <https://research.tib.eu/covid-19/entity/w3a4ogc2_hasAnnotation_C0009117> <https://research.tib.eu/covid-19/entity/w3a4ogc2_hasAnnotation_C0013227> <https://research.tib.eu/covid-19/entity/w3a4ogc2_hasAnnotation_C0018805> <https://research.tib.eu/covid-19/entity/w3a4ogc2_hasAnnotation_C0019080> <https://research.tib.eu/covid-19/entity/w3a4ogc2_hasAnnotation_C0041755> <https://research.tib.eu/covid-19/entity/w3a4ogc2_hasAnnotation_C0687133> <https://research.tib.eu/covid-19/entity/w3a4ogc2_hasAnnotation_C0877248> <https://research.tib.eu/covid-19/entity/w3a4ogc2_hasAnnotation_C0939237>
?:creator	<https://research.tib.eu/covid-19/entity/Charles%2C_Awortwe%3B_Ingolf%2C_Cascorbi>
?:doi	<https://research.tib.eu/covid-19/entity/10.1016/j.phrs.2020.105250>
?:doi	10.1016/j.phrs.2020.105250
?:journal	Pharmacol_Res
?:license	els-covid
?:pdf_json_files	document_parses/pdf_json/8ffe62ab98c42bbac4f277a9ee6ff4332a81b852.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7550259>
?:pmid	<https://research.tib.eu/covid-19/entity/33059010.0>
?:pmid	33059010.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/w3a4ogc2_HAS_C0013227_CAUSES_C0041755> <https://research.tib.eu/covid-19/entity/w3a4ogc2_HAS_C0013227_TREATS_C0007222> <https://research.tib.eu/covid-19/entity/w3a4ogc2_HAS_C0939237_TREATS_C0007222> <https://research.tib.eu/covid-19/entity/w3a4ogc2_HAS_C1145759_TREATS_C0007222>
?:sha_id	<https://research.tib.eu/covid-19/entity/8ffe62ab98c42bbac4f277a9ee6ff4332a81b852>
?:source	Elsevier; Medline; PMC
?:title	Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-10-13

Property

Value

?:abstract

Drug-drug interactions (DDI) potentially occurring between medications used in the course of COVID-19 infection and medications prescribed for the management of underlying comorbidities may cause adverse drug reactions (ADRs) contributing to worsening of the clinical outcome in affected patients. First, we conducted a meta-analysis to determine comorbidities observed in the course of COVID-19 disease associated with an increased risk of worsened clinical outcome from 24 published studies. In addition, the potential risk of DDI between medications used in the course of COVID-19 treatment in these studies and those for the management of observed comorbidities was evaluated for possible worsening of the clinical outcome. Our meta-analysis revealed an implication cardiometabolic syndrome (e.g. cardiovascular disease, cerebrovascular disease, hypertension, and diabetes), chronic kidney disease and chronic obstructive pulmonary disease as main co-morbidities associated with worsen the clinical outcomes including mortality (risk difference RD 0.12, 95%-CI 0.05-0.19, p = 0.001), admission to ICU (RD 0.10, 95%-CI 0.04-0.16, p = 0.001) and severe infection (RD 0.05, 95%-CI 0.01-0.09, p = 0.01) in COVID-19 patients. Potential DDI on pharmacokinetic level were identified between the antiviral agents atazanavir and lopinavir/ritonavir and some drugs, used in the treatment of cardiovascular diseases such as antiarrhythmics and anti-coagulants possibly affecting the clinical outcome including cardiac injury or arrest because of QTc-time prolongation or bleeding. Concluding, DDI occurring in the course of anti-Covid-19 treatment and co-morbidities could lead to ADRs, increasing the risk of hospitalization, prolonged time to recovery or death on extreme cases. COVID-19 patients with cardiometabolic diseases, chronic kidney disease and chronic obstructive pulmonary disease should be subjected to particular carefully clinical monitoring of adverse events with a possibility of dose adjustment when necessary.

is ?:annotates of